Genetic analysis of NFE2L2 promoter variation in Taiwanese Parkinson's disease

Parkinsonism and Related Disorders

Volumn 19, Issue 2, 2013, Pages 247-250

  Chen, Yi Chun ^a   Wu, Yih Ru ^a   Wu, Yi Ci ^b   Lee Chen, Guey Jen ^b   Chen, Chiung Mei ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

Author keywords

Antioxidant response element; Disease association; Oxidative stress; Parkinson's disease; Polymorphism

Indexed keywords

TRANSCRIPTION FACTOR NRF2;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; ETHNIC GROUP; FEMALE; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMICS; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NFE2L2 GENE; OXIDATIVE STRESS; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWANESE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NF-E2-RELATED FACTOR 2; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAIWAN; YOUNG ADULT;

EID: 84873712513     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.10.018     Document Type: Article

References (30)

1. Martin I., Dawson V.L., Dawson T.M. Recent advances in the genetics of Parkinson's disease. Annual Review of Genomics and Human Genetics 2011, 12:301-325.
2. Surmeier D.J., Guzman J.N., Sanchez-Padilla J., Goldberg J.A. The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Antioxidants & Redox Signaling 2011, 14:1289-1301.
3. Schapira A.H., Jenner P. Etiology and pathogenesis of Parkinson's disease. Movement Disorders 2011, 26:1049-1055.
4. Zhou C., Huang Y., Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Annals of the New York Academy of Sciences 2008, 1147:93-104.
5. Abou-Sleiman P.M., Muqit M.M.K., Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nature Reviews Neuroscience 2006, 7:207-219.
6. Nakabeppu Y., Tsuchimoto D., Yamaguchi H., Sakumi K. Oxidative damage in nucleic acids and Parkinson's disease. Journal of Neuroscience Research 2007, 85:919-934.
7. Shamoto-Nagai M., Maruyama W., Hashizume Y., Yoshida M., Osawa T., Riederer P., et al. In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. Journal of Neural Transmission 2007, 114:1559-1567.
8. Sofic E., Sapcanin A., Tahirovic I., Gavrankapetanovic I., Jellinger K., Reynolds G.P., et al. Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases. Journal of Neural Transmission Supplementum 2006, 39-43.
9. Vali S., Mythri R.B., Jagatha B., Padiadpu J., Ramanujan K.S., Andersen J.K., et al. Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. Neuroscience 2007, 149:917-930.
10. Chen C.M., Liu J.L., Wu Y.R., Chen Y.C., Cheng H.S., Cheng M.L., et al. Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease. Neurobiology of Diseases 2009, 33:429-435.
11. Kensler T.W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annual Review of Pharmacology and Toxicology 2007, 47:89-116.
12. Chen P.C., Vargas M.R., Pani A.K., Smeyne R.J., Johnson D.A., Kan Y.W., et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proceedings of the National Academy of Sciences 2009, 106:2933-2938.
13. Mizuta I. Multiple candidate gene analysis identifies -synuclein as a susceptibility gene for sporadic Parkinson's disease. Human Molecular Genetics 2006, 15:1151-1158.
14. Maraganore D.M., de Andrade M., Lesnick T.G., Strain K.J., Farrer M.J., Rocca W.A., et al. High-resolution whole-genome association study of Parkinson disease. The American Journal of Human Genetics 2005, 77:685-693.
15. von Otter M., Landgren S., Nilsson S., Celojevic D., Bergstrom P., Hakansson A., et al. Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Medical Genetics 2010, 11:36.
16. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Archives of Neurology 1999, 56:33-39.
17. Nyholt D.R. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. The American Journal of Human Genetics 2004, 74:765-769.
18. Abecasis G.R., Cookson W.O. GOLD - graphical overview of linkage disequilibrium. Bioinformatics 2000, 16:182-183.
19. Stephens M., Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. The American Journal of Human Genetics 2003, 73:1162-1169.
20. Cheverud J.M. A simple correction for multiple comparisons in interval mapping genome scans. Heredity (Edinb) 2001, 87:52-58.
21. Marzec J.M., Christie J.D., Reddy S.P., Jedlicka A.E., Vuong H., Lanken P.N., et al. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. The FASEB Journal 2007, 21:2237-2246.
22. Peeraully T., Tan E.K. Genetic variants in sporadic Parkinson's disease: east vs west. Parkinsonism & Related Disorders 2012, 18:S63-S65.
23. Nalls M.A., Plagnol V., Hernandez D.G., Sharma M., Sheerin U.M., Saad M., et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649.
24. Simón-Sánchez J., van Hilten J.J., van de Warrenburg B., Post B., Berendse H.W., Arepalli S., et al. Genome-wide association study confirms extant PD risk loci among the Dutch. European Journal of Human Genetics 2011, 19:655-661.
25. Saad M., Lesage S., Saint-Pierre A., Corvol J.C., Zelenika D., Lambert J.C., et al. Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Human Molecular Genetics 2010, 20:615-627.
26. Satake W., Nakabayashi Y., Mizuta I., Hirota Y., Ito C., Kubo M., et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nature Genetics 2009, 41:1303-1307.
27. Simón-Sánchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics 2009, 41:1308-1312.
28. Spencer C.C.A., Plagnol V., Strange A., Gardner M., Paisan-Ruiz C., Band G., et al. Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Human Molecular Genetics 2010, 20:345-353.
29. Müller T., Muhlack S. Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients. Movement Disorders: Official Journal of the Movement Disorder Society 2011, 26:543-546.
30. Müller T., Muhlack S. Cysteine decrease following acute Levodopa intake in patients with Parkinson's disease. Neuroscience Letters 2012, 521:37-39.